Ignite Creation Date:
2024-05-06 @ 5:45 PM
Last Modification Date:
2024-10-26 @ 2:35 PM
Study NCT ID:
NCT05429502
Status:
RECRUITING
Last Update Posted:
2024-05-13
First Post:
2022-06-17
Brief Title:
Study of Efficacy and Safety of Ribociclib LEE011 in Combination With Topotecan and Temozolomide TOTEM in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Organization Data
Organization:
Novartis
Class:
INDUSTRY
Study ID:
CLEE011Q12101
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Novartis Pharmaceuticals
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Innovative Therapies For Children with Cancer Consortium | OTHER |